$SGRY

Why Is Surgery Partners Stock Gaining Friday? - Surgery Partners (NASDAQ:SGRY)

Surgery Partners (SGRY) said it will sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for about $795 million, valuing the facilities at roughly $1.15 billion, subject to physician partner approval. The company reaffirmed fiscal 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million.

Original reporting
Published Jul 24, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 24, 2026, 7:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Is Surgery Partners Stock Gaining Friday? - Surgery Partners (NASDAQ:SGRY) — source image
Decision brief

The 30-second read

$SGRYBullishMed
01

Why it matters

The announced sale to Intermountain for about $795M, alongside reaffirmed FY26 revenue ($3.35B to $3.45B) and adjusted EBITDA (at least $530M), provides a fresh catalyst and reduces guidance uncertainty, supporting the stock’s bullish move.

02

Market read

A large, specific facility sale plus reaffirmed FY26 guidance is a tradable catalyst, with the main swing factor being physician-partner approval and deal execution.

03

What to watch

The article does not specify expected proceeds usage, deal-related costs, or how the sale changes segment margins, so traders may need to wait for filings or investor materials for the true earnings impact.

Relevance 7/10Novelty 6/10Timing: Friday price move tied to the announced facility sale and reaffirmed FY26 guidance.

Background

Surgery Partners is a surgical services provider pursuing portfolio optimization and emphasizing ambulatory surgery center growth.

Company-level read

Ticker impact

$SGRYBullishMedium confidence
Context

Surgery Partners agreed to sell Idaho Falls and Mountain View hospital facilities to Intermountain for about $795M, plus reaffirmed FY26 revenue and EBITDA guidance.

Expected impact

Shares may remain bid into the deal-approval process, but upside could be capped by execution and physician-partner approval risk.

Evidence & confidence

The article provides deal size ($795M) and valuation context ($1.15B) and pairs it with reaffirmed FY26 guidance, which can reduce uncertainty. However, it does not quantify deal timing, closing conditions beyond physician approval, or expected financial impact beyond guidance.

Market effects

Could reinforce investor appetite for ambulatory surgery center operators and portfolio simplification among surgical services providers.

Limited to the Idaho Falls and Mountain View hospital footprint, with potential local competitive and referral shifts.

Low, as the transaction is primarily domestic healthcare operations with no stated cross-border implications.

Counterpoint

The deal could be viewed as shrinking hospital exposure rather than growing earnings power, and the market may later discount the transaction if physician-partner approval or closing timing slips.

Key entities

  • Surgery Partners

    NASDAQ-listed surgical services provider announcing the sale of Idaho Falls and Mountain View hospital ownership interests to Intermountain.

  • Intermountain Health

    Health system acquiring the hospital facilities from Surgery Partners.

  • Eric Evans

    CEO of Surgery Partners commenting on the transaction’s role in portfolio optimization and ambulatory surgery center momentum.

Related articles

$SGRYMedAI 8/10

Surgery Partners jumps on $1.15B hospital sale deal By Investing.com

Surgery Partners (NASDAQ:SGRY) rose 5.8% after agreeing to sell two Idaho Falls hospitals to Intermountain Health for about $1.15B. Surgery Partners expects about $795M for its ownership interests, with cash proceeds subject to purchase price adjustments. The deal needs approvals and regulatory steps and is expected to close in coming months. 2026 outlook was reaffirmed excluding the deal.

$SGRYMedAI 8/10

Surgery Partners To Sell 2 Idaho Hospitals To Intermountain For $795 Mln, Backs FY View; Shares Jump

Surgery Partners (SGRY) said it signed agreements to sell its interests in Mountain View Hospital and Idaho Falls Community Hospital in Idaho to Intermountain Health for about $795 million. The hospitals were valued around $1.15 billion. Surgery Partners reaffirmed its FY2026 revenue of $3.35B to $3.45B and adjusted EBITDA of at least $530M excluding the deal. Shares rose to about $16.51.

$SGRYMed

Why Surgery Partners (SGRY) Stock Is Trading Up Today

Surgery Partners (SGRY) shares rose about 2.7% in the morning to around $17.15 after Cantor Fitzgerald reiterated an “Overweight” rating and set an $18.00 price target. Cantor cited some softness in Q2 ambulatory surgery center and outpatient nursing data, but kept a positive view. Other analysts expect profitability this year.

MedAI 9/10

Nielsen To Buy DoubleVerify For $2.15 Billion In Ad Measurement Deal

Nielsen agreed to buy DoubleVerify in an all-cash deal valued at about $2.15 billion, paying $13.60 per share, a 30% premium to the stock’s 60-day VWAP as of Aug. 5. The boards approved; closing is expected by Q1 2027, subject to approvals. Pro forma revenue is expected to exceed $4 billion.

$RTXMedAI 8/10

RTX wins up to $745.4 million deal for SM-3 Block IIA interceptors, extending ballistic missile interceptor production through 2031

RTX won a U.S. Department of War deal worth up to $745.4 million for SM-3 Block IIA ballistic missile interceptors, extending production through 2031. The first tranche totals $275.6 million from the U.S. defense budget and $277.6 million from Japan’s MoD. SM-3 Block IIA uses a kinetic warhead and Mk 41 launchers. It saw documented combat use in April 2024 against Iranian missiles.